Baidu
map

政策与人文

订阅

MedSci主页 / 所有栏目 / 政策与人文

2013年生物医药行业并购案Top25

2014-02-10 MedSci MedSci原创

并购生物医药
关注

23.25pt; pADDinG-riGHT: 0.75pt; pADDinG-Top: 0pt" valign="center" width="31">   原料药、抗感染药 Akorn Inc Hi-Tech Pharmacal 6.4 24%

23.25pt; pADDinG-riGHT: 0.75pt; pADDinG-Top: 0pt" valign="center" width="31">

 

原料药、抗感染药

Akorn Inc

Hi-Tech Pharmacal

6.4

24%

仿制药、非处方药

Pharmstandard

Bever Pharma

5.9

 

新加坡非处方药

Ref: Top 25 M&A Deals of 2013

,
2009-2012总M&A交易额持续下滑，分别为1520亿、1090亿、550亿、430亿美元，2013年欧美生物医药产业全面复苏，M&A也跟着呈现大反弹。Top25并购案如下（单位：亿美元）。

收购方

被收购方

交易额

溢价

相关产品/业务

Thermo Fisher

Life Tech

136

12%

生物实验室相关试剂、仪器

Amgen

Onyx Pharma

104

44%

sorafenib、regorafenib、carfilzomib、palbociclib

Valeant Pharma

Bausch+Lomb

87

 

眼科用药品、护理用品

Perrigo Company

Elan Corp

86

10%

natalizumab、ELND005等

Actavis Inc

Warner Chlicott

85

 

女性用药品

AstraZeneca

BMS分部

43

 

saxagliptin、dapagliflozin、exenatide

Shire plc

ViroPharma

42

27%

Cinryze、孤儿药

Bayer

Algeta

29

37%

Xofigo（镭-223）、钍-227

NewCo

Patheon Inc

26

64%

CRO业务

Salix Pharma

Santarus Inc

26

36%

品牌仿制药

Mylan Inc

Agila

17.5

 

注射剂业务

Grifols

Novartis分部

16.75

 

输血诊断业务

Madison Dearborn

Ikaria Inc

16

 

Inomax（NO吸入剂）

Endo

Paladin Labs

16

20%

加拿大仿制药

KKR & Co LP

PRA International

13

 

CRO业务

AstraZeneca

Pearl Therapeutics

11.5

 

PT003（格隆溴铵/福莫特罗）

GlaxoSmithKline

GSK-India

10.28

26%

GSK印度分部

Jazz Pharma

Gentium SpA

10

2%

肝静脉阻塞新药defibrotide

Johnson & Johnson

Aragon Pharma

10

 

前列腺癌新药ARN-509

Allergan Inc

MAP Pharma

9.58

60%

Levadex（双氢麦角胺喷雾剂）

Otsuka Pharma

Astex Pharma

8.86

48%

基于碎片的药物设计平台及相关新药

Cubist Pharma

Trius Therapeutics

7.04

15%

耐药菌新药TR-701

Novo Nordisk

Xellia Pharma

7

 本文系梅斯医学（MedSci）原创编译整理，转载需授权！-->
版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1408628, encodeId=fedd1408628e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Feb 12 00:54:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468773, encodeId=5ce51468e73cb, content=<a href='/topic/show?id=ce0049043f3' target=_blank style='color:#2F92EE;'>#并购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49043, encryptionId=ce0049043f3, topicName=并购)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6fbc6938060, createdName=canlab, createdTime=Wed Feb 12 00:54:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604943, encodeId=2dad16049431e, content=<a href='/topic/show?id=a631353e6e6' target=_blank style='color:#2F92EE;'>#医药行业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35376, encryptionId=a631353e6e6, topicName=医药行业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbd19305036, createdName=fmq_28614559, createdTime=Wed Feb 12 00:54:00 CST 2014, time=2014-02-12, status=1, ipAttribution=)]
    2014-02-12 cathymary

    #医药#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1408628, encodeId=fedd1408628e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Feb 12 00:54:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468773, encodeId=5ce51468e73cb, content=<a href='/topic/show?id=ce0049043f3' target=_blank style='color:#2F92EE;'>#并购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49043, encryptionId=ce0049043f3, topicName=并购)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6fbc6938060, createdName=canlab, createdTime=Wed Feb 12 00:54:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604943, encodeId=2dad16049431e, content=<a href='/topic/show?id=a631353e6e6' target=_blank style='color:#2F92EE;'>#医药行业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35376, encryptionId=a631353e6e6, topicName=医药行业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbd19305036, createdName=fmq_28614559, createdTime=Wed Feb 12 00:54:00 CST 2014, time=2014-02-12, status=1, ipAttribution=)]
    2014-02-12 canlab

    #并购#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1408628, encodeId=fedd1408628e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Feb 12 00:54:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468773, encodeId=5ce51468e73cb, content=<a href='/topic/show?id=ce0049043f3' target=_blank style='color:#2F92EE;'>#并购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49043, encryptionId=ce0049043f3, topicName=并购)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6fbc6938060, createdName=canlab, createdTime=Wed Feb 12 00:54:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604943, encodeId=2dad16049431e, content=<a href='/topic/show?id=a631353e6e6' target=_blank style='color:#2F92EE;'>#医药行业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35376, encryptionId=a631353e6e6, topicName=医药行业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbd19305036, createdName=fmq_28614559, createdTime=Wed Feb 12 00:54:00 CST 2014, time=2014-02-12, status=1, ipAttribution=)]
    2014-02-12 fmq_28614559

    #医药行业#

    0

Baidu
Baidu
Baidu
Baidu